Public Companies
Reunion Neuroscience Exec Steps Down as Director
Psychedelic drug maker Reunion Neuroscience (Nasdaq: REUN), formerly known as Field Trip Health, announced that Ronan Levy has stepped down from the board…

Psychedelic drug maker Reunion Neuroscience (Nasdaq: REUN), formerly known as Field Trip Health, announced that Ronan Levy has stepped down from the board and resigned his post as director.
Levy co-founded Field Trip Health.
The company’s corporate secretary and general counsel, Paula Amy Hewitt, also resigned.
“The company wishes both Ronan and Paula much success in their future endeavors and greatly appreciates the contributions that they made to support Reunion as it transitioned to a stand-alone entity,” a spokesperson told Green Market Report.
The news follows Reunion’s recent tapping of Greg Mayes as president and CEO. Mayes has been poised to replace Levy since the Sept. 28 announcement.
A company spokesperson said that Hewitt served Reunion as corporate secretary, but “was not employed by the company.”
“As such, Reunion needed to align its board support with an existing employee,” the spokesperson added.
CFO Donna Wong will fill Hewitt’s post as legal advisor.
The post Reunion Neuroscience Exec Steps Down as Director appeared first on Green Market Report.
psychedelic nasdaq field trip health field trip
-
LSD16 hours ago
Cannabis Coalition Forms To Push Biden On Federal Reform: Will It Work This Time?
-
LSD16 hours ago
Study Shows New Mechanism For How Psychedelics Promote Plasticity
-
Public Companies15 hours ago
Nirvana Moves Forward With MedSmart Acquisition
-
Psilocybin14 hours ago
Enveric Biosciences Announces Two Poster Presentations at the Canadian Chemistry Conference and Exhibition (CSC 2023)
-
Markets & Investing14 hours ago
Psychedelics in Dubai: Therapeutic Role of Psychedelics Explored at Conference in the Arab Region
-
Psilocybin6 hours ago
Oregon Pioneers New Psilocybin Business Models
-
Markets & Investing4 hours ago
The 7 Most Promising Penny Stocks to Buy in June